Short answer
Viatris (VTRS) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $3.7B (up 0.3% year over year) with net income of −$128M.
Q3 2025 key financials · XBRL
- Revenue
- $3.7B
- +0.3% YoY · +5.0% QoQ
- Net income
- −$128M
- −235.2% YoY · −2687.0% QoQ
- Operating margin
- 4.8%
- Gross margin
- 36.6%
- EPS (diluted)
- −$0.12
- −250.0% YoY · −300.0% QoQ
Source: XBRL data from the Viatris (VTRS) Q3 2025 10-Q on SEC EDGAR. USD.
Viatris Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $3.76B Q3 2025, flat YoY ($3.75B Q3 2024); 9-month revenue $10.60B down 5% YoY ($11.21B 2024)
- Gross margin decreased to 36% Q3 2025 from 39% Q3 2024; 9-month margin 36% vs 39% YoY due to Indore facility impact
- Best segment: Greater China up 10% Q3 2025 ($615M vs $562M); worst segment: JANZ down 11% Q3 2025 ($306M vs $344M)
- Operating cash flow $1.5B for 9 months 2025, down $320M YoY; cash repurchases $418M YTD with $975M cash on hand Sept 30, 2025
- Management cites $2.94B goodwill impairment Q1 2025, ongoing FDA remediation at Indore plant affecting ~$400M revenue reduction YTD, expects 2026 reinspection
Risk Factors
- New risk: Potential tariffs up to 15% on brand pharmaceuticals from EU due to new bilateral trade agreements
- Material update: Increased cost of goods and supply chain disruptions from proposed tariffs on pharmaceutical imports and APIs
- Regulatory risk: Need for regulatory approval delays adapting manufacturing or suppliers under new trade restrictions
- Operational risk: Competitors may gain advantage if tariffs disproportionately impact Viatris’ sourcing or supply agreements
- Financial risk: Tariffs and trade restrictions risk reducing profit margins, potentially making some product lines unsustainable
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Viatris quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.